Navicixizumab (Anti-DLL4)
Product Specifications
CAS Number
1638338-43-8
Synonyms
OMP-305B83; Anti-DLL4 Reference Antibody
Additionnal Information
Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4/VEGF. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470177-500 1x 500 µL
CD50 (ICAM-3) (101-1D2), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040676-100 1x 100 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC941820-100 1x 100 µL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040034-100 1x 100 µL
Cytokeratin 8/18 (C-51), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401003-500 1x 500 µL
Mucin 5AC (MUC5AC) (58M1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details